EyePoint Pharmaceuticals, Inc. (EYPT) News

EyePoint Pharmaceuticals, Inc. (EYPT)

Today's Latest Price: $0.87 USD

0.01 (1.15%)

Updated Jun 1 9:36am

Add EYPT to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

Filter EYPT News Items

EYPT News Results

Event/TimeSymbolCompanyNews DetailStartEndChangePOWR Rating
Loading, please wait...

Latest EYPT News From Around the Web

Below are the latest news stories about EyePoint Pharmaceuticals Inc that investors may wish to consider to help them evaluate EYPT as an investment opportunity.

Should You Buy EyePoint Pharmaceuticals, Inc. (EYPT)?

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each […]

Yahoo | May 27, 2020

EyePoint Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

WATERTOWN, Mass., May 26, 2020 -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic.

Yahoo | May 26, 2020

Edited Transcript of EYPT earnings conference call or presentation 6-May-20 12:30pm GMT

Q1 2020 EyePoint Pharmaceuticals Inc Earnings Call

Yahoo | May 25, 2020

EyePoint Pharmaceuticals Presents Data Showcasing DEXYCU® at the American Society of Cataract and Refractive Surgery 2020 Virtual Annual Meeting

WATERTOWN, Mass., May 18, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and…

GlobeNewswire | May 18, 2020

EyePoint Pharmaceuticals Reports First Quarter 2020 Financial Results and Highlights Recent Corporate Developments

- Total revenues of $7.5 million and net product revenues of $4.7 million - - Cash conservation and reorganization initiatives coupled…

GlobeNewswire | May 6, 2020

EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Tops Revenue Estimates

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -10.00% and 7.83%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | May 6, 2020

EyePoint Pharmaceuticals: Q3 Earnings Insights

Shares of EyePoint Pharmaceuticals (NASDAQ:EYPT) were flat in pre-market trading after the company reported Q3 results.Quarterly Results Earnings per share were up 45.00% year over year to ($0.11), which missed the estimate of ($0.10).Revenue of $7,489,000 higher by 272.22% year over year, which beat the estimate of $7,250,000.Outlook Earnings guidance hasn't been issued by the company for now.Revenue guidance hasn't been issued by the company for now.Details Of The Call Date: May 06, 2020View more earnings on EYPTWebcast URL: https://edge.media-server.com/mmc/p/wmbgnxa6Technicals 52-week high: $2.6952-week low: $0.70Price action over last quarter: down 30.08%Company Profile EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthal...

Yahoo | May 6, 2020

EyePoint Pharmaceuticals Announces First Quarter 2020 Financial Results Release Date and Conference Call Information

WATERTOWN, Mass., April 29, 2020 -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic.

Yahoo | April 29, 2020

Sage slashes 53% of staff as hospitals cut inpatient stays

One of the industry’s highly watched neuroscience drugmakers is cutting more than half of its workforce as it works to revive hope for its sophomore drug candidate and weather a drop in sales.

Yahoo | April 8, 2020

The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 2) BELLUS Health Inc (NASDAQ: BLU ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows April 2) BIOLASE Inc (NASDAQ: BIOL ) BioNano Genomics Inc (NASDAQ: BNGO ) (priced $18 million common stock and warrant offering) Celcuity Inc (NASDAQ: CELC ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) ENDRA Life Sciences Inc (NASDAQ: NDRA ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) Mediwound Ltd (NASDAQ: MDWD ) Merus NV (NASDAQ: MRUS ) Myokardia Inc (NASDAQ: MYOK ) Neovasc Inc (NASDAQ: NVCN ) Opko Health Inc. (NASDAQ: OPK ) PDS Biotechnology Corp (NASDAQ: PDSB ) Ph...

Benzinga | April 3, 2020

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7108 seconds.